{
    "clinical_study": {
        "@rank": "87300", 
        "arm_group": [
            {
                "arm_group_label": "VX-135 High Dose with Daclatasvir", 
                "arm_group_type": "Experimental", 
                "description": "12 weeks of a high dose of VX-135 in combination with Daclatasvir"
            }, 
            {
                "arm_group_label": "VX-135 Low Dose with Daclatasvir", 
                "arm_group_type": "Experimental", 
                "description": "12 weeks of a low dose of VX-135 in combination with Daclatasvir"
            }
        ], 
        "brief_summary": {
            "textblock": "A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of\n      VX-135 and Daclatasvir in Treatment-Na\u00efve Adult Subjects With Genotype 1 Chronic Hepatitis C"
        }, 
        "brief_title": "A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Hepatitis C", 
            "CHC", 
            "HCV", 
            "Hepatitis C"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have genotype 1 CHC and evidence of HCV infection at least 6 months\n             before screening\n\n          -  Subjects must be treatment-na\u00efve and have not received prior treatment with any\n             interferon, immunomodulatory agent, or DAA for HCV\n\n        Exclusion Criteria:\n\n          -  Evidence of cirrhosis\n\n          -  History or other clinical evidence of significant or unstable cardiac disease\n\n          -  Any other cause of significant liver disease in addition to hepatitis C\n\n          -  Creatinine clearance \u226450 mL/min using the Cockcroft-Gault equation at screening\n\n          -  Female subjects who are pregnant or nursing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842451", 
            "org_study_id": "VX13-135-105"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "VX-135 High Dose with Daclatasvir", 
                    "VX-135 Low Dose with Daclatasvir"
                ], 
                "intervention_name": "VX-135", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "VX-135 High Dose with Daclatasvir", 
                    "VX-135 Low Dose with Daclatasvir"
                ], 
                "intervention_name": "Daclatasvir", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand"
                    }, 
                    "name": "New Zealand"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Christchurch", 
                        "country": "New Zealand"
                    }, 
                    "name": "New Zealand"
                }
            }
        ], 
        "location_countries": {
            "country": "New Zealand"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Multicenter, Randomized, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Treatment-Na\u00efve Adult Subjects With Genotype 1 Chronic Hepatitis C", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "New Zealand: Medsafe", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The safety and tolerability as assessed by adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs), echocardiograms, and laboratory assessments", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 64 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842451"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The proportion of subjects who have a sustained virologic response (SVR; i.e., HCV RNA concentration below the lower limit of quantitation [<LLOQ; <25 IU/mL]) at 4 weeks after the last planned dose of treatment (SVR4)", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 Weeks"
            }, 
            {
                "measure": "The proportion of subjects who have an SVR at 12 weeks after the last planned dose of treatment (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 weeks"
            }, 
            {
                "measure": "The proportion of subjects who have an SVR at 44 weeks after the last planned dose of treatment (SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Up to 40 weeks"
            }, 
            {
                "measure": "The proportion of subjects who have virologic relapse", 
                "safety_issue": "No", 
                "time_frame": "Up to 64 weeks"
            }, 
            {
                "measure": "The proportion of subjects who have virologic breakthrough", 
                "safety_issue": "No", 
                "time_frame": "Up to 16 weeks"
            }, 
            {
                "measure": "The amino acid sequence of the nonstructural NS5A and NS5B proteins in subjects who have treatment failure", 
                "safety_issue": "No", 
                "time_frame": "Up to 64 weeks"
            }, 
            {
                "measure": "The proportion of subjects who achieve SVR12 by HCV genotype 1 subtype (1a versus non-1a)", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 weeks"
            }, 
            {
                "measure": "The proportion of subjects who achieve SVR12 by IL-28B genotype (CC versus non-CC)", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 weeks"
            }
        ], 
        "source": "Vertex Pharmaceuticals Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vertex Pharmaceuticals Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}